Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
The MS Center of Northeastern New York
mi
from
Latham, NY
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
The MS Center of Northeastern New York
mi
from
Latham, NY
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Winthrop University Hospital
mi
from
Mineola, NY
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
South Shore Neurologic Associates
mi
from
Patchogue, NY
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
South Shore Neurologic Associates
mi
from
Patchogue, NY
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Island Neurological Associates
mi
from
Plainview, NY
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Island Neurological Associates
mi
from
Plainview, NY
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Stony Brook University Medical Center
mi
from
Stony Brook, NY
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Raleigh Neurology Associates
mi
from
Raleigh, NC
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Raleigh Neurology Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
UC Health Clinical Trials Office
mi
from
Cincinnati, OH
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
UC Health Clinical Trials Office
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation; Cleveland Clinic Cancer Center/I40
mi
from
Cleveland, OH
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation; Cleveland Clinic Cancer Center/I40
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Ohio State University, Wexner Medical Center, Department of Neurology
mi
from
Columbus, OH
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Ohio State University, Wexner Medical Center, Department of Neurology
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Neurology Specialists
mi
from
Dayton, OH
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Neurology Specialists
mi
from
Dayton, OH
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Providence Multiple Sclerosis Center
mi
from
Portland, OR
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Providence Multiple Sclerosis Center
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Allegheny Neurological Associates
mi
from
Pittsburgh, PA
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Allegheny Neurological Associates
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Neurology Clinic, PC
mi
from
Cordova, TN
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Neurology Clinic, PC
mi
from
Cordova, TN
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Hope Neurology
mi
from
Knoxville, TN
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Hope Neurology
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Uni of Texas Health Science Center At Houston
mi
from
Houston, TX
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Uni of Texas Health Science Center At Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Bhupesh Dihenia, M.D., P.A.
mi
from
Lubbock, TX
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Bhupesh Dihenia, M.D., P.A.
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Central Texas Neurology Consultants, P.A.
mi
from
Round Rock, TX
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Central Texas Neurology Consultants, P.A.
mi
from
Round Rock, TX
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Neurology Center of San Antonio
mi
from
San Antonio, TX
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Neurology Center of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain MS Clinic
mi
from
Salt Lake City, UT
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain MS Clinic
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Neurological Associates Inc; Clinical Research
mi
from
Richmond, VA
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Neurological Associates Inc; Clinical Research
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Swedish Neuroscience Institute
mi
from
Seattle, WA
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Swedish Neuroscience Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Multicare Health System Institute for Research and Innovation
mi
from
Tacoma, WA
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Multicare Health System Institute for Research and Innovation
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Foothills Medical Centre; Centre Dept of Medical Clinical Neuroscience
mi
from
Calgary,
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Foothills Medical Centre; Centre Dept of Medical Clinical Neuroscience
mi
from
Calgary,
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine; Department of Neurology
mi
from
Saint Louis, MO
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine; Department of Neurology
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Neurology and Neuroscience Assoc., Inc.
mi
from
Westerville, OH
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Neurology and Neuroscience Assoc., Inc.
mi
from
Westerville, OH
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
IMMUNOe Research Centers
mi
from
Centennial, CO
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
IMMUNOe Research Centers
mi
from
Centennial, CO
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
mi
from
Washington,
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated:  12/31/1969
Neurology Center of New England
mi
from
Foxboro, MA
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status: Enrolling
Updated: 12/31/1969
Neurology Center of New England
mi
from
Foxboro, MA
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cullman, AL
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cullman, AL
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boca Raton, FL
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New Port Richey, FL
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fulton, MD
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fulton, MD
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Deckerville, MI
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Deckerville, MI
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Stratford, NJ
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Stratford, NJ
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Teaneck, NJ
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Staten Island, NY
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Staten Island, NY
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lititz, PA
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lititz, PA
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Franklin, TN
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Franklin, TN
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lubbock, TX
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lubbock, TX
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fairfax, VA
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
mi
from
Bala-Cynwyd, PA
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
mi
from
Bala-Cynwyd, PA
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Medford, OR
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Virginia Beach, VA
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Virginia Beach, VA
Click here to add this to my saved trials